Phibro Animal Health (PAHC) Cash from Financing Activities (2013 - 2026)

Phibro Animal Health's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 92.86% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was -$12.7 million, a 105.87% decrease from a year earlier, with the FY2025 full-year figure at $207.1 million, up 3160.49% from the prior year.
• Cash from Financing Activities grew to -$2.3 million in Q1 2026 per PAHC's latest filing, from -$19.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $276.3 million in Q4 2024 and bottomed at -$32.2 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is $1.3 million (2023), against an average of $14.4 million.
• Biggest YoY gain for Cash from Financing Activities was 1979.09% in 2024; the steepest drop was 2352.85% in 2024.
• Year by year, Cash from Financing Activities stood at $3.7 million in 2022, then plunged by 495.72% to -$14.7 million in 2023, then surged by 1979.09% to $276.3 million in 2024, then slumped by 106.87% to -$19.0 million in 2025, then surged by 87.88% to -$2.3 million in 2026.
• Per Business Quant, the three latest PAHC Cash from Financing Activities figures stand at -$2.3 million (Q1 2026), -$19.0 million (Q4 2025), and $16.3 million (Q3 2025).